Rhythm begins long-term phase 2 enrollment for an oral MC4R agonist

A new clinical trial has begun for bivamelagon, an oral medicine being tested in people with hypothalamic obesity (HO), according to a study record posted on ClinicalTrials.gov under identifier NCT07156578 and titled "A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)" ^[1]. The listing confirms the drug's name, the condition being studied, and that the trial is designed to look at long-term use, but the registration text reviewed for this story does not spell out the planned number of participants, the exact start date, or the trial phase ^[1].

Hypothalamic obesity is a rare, severe form of obesity that can occur after damage to the hypothalamus, a brain region that helps regulate hunger and energy use. Damage often follows surgery or radiation for brain tumors. Bivamelagon works on the melanocortin-4 receptor, or MC4R, a pathway in that same hunger-signaling circuit ^[1]. The trial record lists standard ClinicalTrials.gov eligibility categories, including age-group classifications that run from "Child (birth–17)" through "Older Adult (65+)" and "Adult (18–64)," though the specific age range enrolled in this particular study is not detailed in the material reviewed ^[1].

Because the source reviewed here is largely a general glossary of ClinicalTrials.gov terms attached to the study record, several details commonly expected in trial coverage — such as the exact enrollment target, the study's sponsor as named in the record, the comparator arm, and specific start or completion dates — are not yet confirmed from the available text ^[1]. Readers should treat those specifics as not yet known until Rhythm Pharmaceuticals or the registry itself publishes fuller details.

Why it matters for patients

For families managing hypothalamic obesity, treatment options are limited. An oral MC4R agonist that works over the long term could matter because it would not require a daily injection, which is a meaningful consideration for very young children and for caregivers managing chronic treatment routines. Because this is a long-term study rather than a first-in-human trial, it suggests bivamelagon has already gone through earlier testing stages, though the exact prior results are not part of the source reviewed here ^[1].

It is important to understand that this is an investigational drug. Bivamelagon has not been approved by the FDA, and nothing in the available trial record indicates efficacy or safety outcomes at this stage ^[1]. People interested in hypothalamic obesity treatment should not assume any results, timeline, or availability based on a study opening for enrollment.

What happens next

The study record does not specify a target completion date or interim readout dates in the reviewed material ^[1]. As is typical with ClinicalTrials.gov records, updates such as enrollment numbers, participating sites, and outcome measures are usually added or revised as a trial progresses, so more specific numbers may appear on the registry over time. Until then, the scope of who can enroll, how many patients the study aims to include, and how long participants will be followed remain unclear based on the information available ^[1]. Patients and caregivers following this program will need to watch for future updates from Rhythm Pharmaceuticals or amended ClinicalTrials.gov postings for firmer details on trial size, timeline, and design.